Kanazawa H, Takahashi K, Hanazawa Y, Uchiyama S, Takahara T, Takahara M, Muto M, Kinehara M, Sato K
Dept. of Oral Surgery, School of Medicine, Chiba University.
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 1):775-80.
To determine the effect of continuous subcutaneous infusion of peplomycin on both antitumor activity and pulmonary toxicity, thirty-two patients with previously untreated oral squamous carcinoma were given peplomycin via osmotic microinfusion pump (SP-5, Nipro Co., Ltd.) at a daily dose of 5.0 mg subcutaneously. The mean dosage of peplomycin given was 79.8 mg. An overall response rate of 62.5% was achieved, with 21.9% complete response, and 40.6% partial response. The maximum reduction of tumor volume for responder could be generally observed when peplomycin was given at about 60 mg continuously. The most frequently encountered toxicity was a mucocutaneous reaction, manifested by stomatitis (34.4%) and skin eruption (18.8%), but they were mild and tolerable. A local skin reaction also occurred at the site of drug injection, and an ulcer formation developed in 12.5% of patients. Monitoring of pulmonary function by means of PaO2 revealed that 32.0% of patients had a decrease over 10% after peplomycin administration. However, interstitial pneumonitis eventually occurred in only one patient (3.1%). In conclusion, the regimen of continuous infusion of peplomycin is a useful method to administer peplomycin safely without reducing the antitumor effect compared to conventional intermittent injection.
为确定持续皮下输注培普利霉素对抗肿瘤活性和肺部毒性的影响，32例未经治疗的口腔鳞状细胞癌患者通过渗透式微量输注泵（SP - 5，日机装株式会社）皮下给予培普利霉素，每日剂量为5.0mg。培普利霉素的平均给药剂量为79.8mg。总缓解率为62.5%，其中完全缓解率为21.9%，部分缓解率为40.6%。一般在连续给予培普利霉素约60mg时，可观察到缓解者的肿瘤体积最大程度缩小。最常出现的毒性反应是皮肤黏膜反应，表现为口腔炎（34.4%）和皮疹（18.8%），但症状较轻且可耐受。在药物注射部位也出现局部皮肤反应，12.5%的患者出现溃疡形成。通过监测动脉血氧分压（PaO₂）评估肺功能发现，32.0%的患者在给予培普利霉素后下降超过10%。然而，最终仅1例患者（3.1%）发生间质性肺炎。总之，与传统间歇注射相比，持续输注培普利霉素方案是一种在不降低抗肿瘤效果的情况下安全给药培普利霉素的有效方法。
